1. Home
  2. VYNE vs MNDR Comparison

VYNE vs MNDR Comparison

Compare VYNE & MNDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYNE
  • MNDR
  • Stock Information
  • Founded
  • VYNE 2003
  • MNDR 2016
  • Country
  • VYNE United States
  • MNDR Singapore
  • Employees
  • VYNE N/A
  • MNDR N/A
  • Industry
  • VYNE Biotechnology: Pharmaceutical Preparations
  • MNDR
  • Sector
  • VYNE Health Care
  • MNDR
  • Exchange
  • VYNE Nasdaq
  • MNDR Nasdaq
  • Market Cap
  • VYNE 7.9M
  • MNDR 9.3M
  • IPO Year
  • VYNE 2018
  • MNDR 2024
  • Fundamental
  • Price
  • VYNE $0.43
  • MNDR $3.97
  • Analyst Decision
  • VYNE Buy
  • MNDR
  • Analyst Count
  • VYNE 2
  • MNDR 0
  • Target Price
  • VYNE $8.00
  • MNDR N/A
  • AVG Volume (30 Days)
  • VYNE 3.1M
  • MNDR 273.2K
  • Earning Date
  • VYNE 11-06-2025
  • MNDR 11-16-2025
  • Dividend Yield
  • VYNE N/A
  • MNDR N/A
  • EPS Growth
  • VYNE N/A
  • MNDR N/A
  • EPS
  • VYNE N/A
  • MNDR N/A
  • Revenue
  • VYNE $476,000.00
  • MNDR $11,600,567.00
  • Revenue This Year
  • VYNE N/A
  • MNDR $188,831.77
  • Revenue Next Year
  • VYNE N/A
  • MNDR $76.44
  • P/E Ratio
  • VYNE N/A
  • MNDR N/A
  • Revenue Growth
  • VYNE N/A
  • MNDR 0.61
  • 52 Week Low
  • VYNE $0.28
  • MNDR $3.33
  • 52 Week High
  • VYNE $4.30
  • MNDR $40.00
  • Technical
  • Relative Strength Index (RSI)
  • VYNE 60.37
  • MNDR 69.95
  • Support Level
  • VYNE $0.32
  • MNDR $3.70
  • Resistance Level
  • VYNE $0.35
  • MNDR $3.93
  • Average True Range (ATR)
  • VYNE 0.02
  • MNDR 0.32
  • MACD
  • VYNE 0.02
  • MNDR 0.04
  • Stochastic Oscillator
  • VYNE 84.88
  • MNDR 82.07

About VYNE VYNE Therapeutics Inc.

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

About MNDR Mobile-health Network Solutions Class A Ordinary Shares

Mobile-health Network Solutions is a company engaged in providing telehealth solutions in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application. It provides services on its MaNaDr platform, which is accessible via mobile application and website. The MaNaDr platform is a platform designed and created by doctors, for doctors and users, equipped with services like consultations with doctors, e-commerce pharma store, and others. The company's operating segments are Telemedicine and other services which is also its key revenue generating segment, and Sale of medicine and medical devices. Geographically, it derives revenue from Singapore.

Share on Social Networks: